health pharma news today obesity drugs glp-1 Could weight-loss eat the world? Data Brief: GLP-1 Prescriptions for

Nat Rev Endocrinol Nature Publishing Group

Results of randomized trials Six large randomized trials and a post hoc analysis 1521 have investigated the safety and efficacy of GLP-1 receptor agonists in patients with type 2 diabetes who also either had known cardiovascular disease or were at high risk of it, using a composite of major adverse cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes) as the primary end point (Table 2)

[DOI] [PMC free article] [PubMed] [Google Scholar] 741.Alhadeff A.L., Rupprecht L.E., Hayes M.R

DPP-4i = dipeptidyl peptidase-4 inhibitor

Although clinical, empirical data guides medical practice, every patient is unique and deserves individualized considerations

Choose injectable or oral compounded GLP-1